Single Source: Accelerating Medicines Partnership Schizophrenia (AMP SCZ): Clinical Trial Data Processing, Analysis, and Coordination Center
NIMH plans to renew funding for a center at Brigham and Women's Hospital to manage, process, and analyze clinical trial data for the AMP Schizophrenia network, supporting research on psychosis interventions.
Funder: National Institutes of Health
Due Dates: June 9, 2026 (Full application deadline)
Funding Amounts: Up to $5,000,000 total; one award anticipated; project duration not specified.
Summary: Supports continuation of the AMP® SCZ Data Processing, Analysis, and Coordination Center to complete processing and analysis of longitudinal schizophrenia biomarker and clinical outcome data.
Key Information: Only Brigham and Women's Hospital is eligible to apply.
Description
This funding opportunity, issued by the National Institute of Mental Health (NIMH), is a single-source cooperative agreement to support the continuation of the Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ) Data Processing, Analysis, and Coordination Center (DPACC). The award is intended to enable DPACC to complete the processing and analysis of longitudinal, multi-modal biomarker and clinical outcome data collected over 24 months as part of the AMP® SCZ initiative. The program emphasizes the integration and analysis of complex datasets to advance understanding and treatment of schizophrenia.
